DAXSINIG Trademark

Trademark Overview

On Thursday, November 2, 2017, a trademark application was filed for DAXSINIG with the United States Patent and Trademark Office. The USPTO has given the DAXSINIG trademark a serial number of 87669502. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, August 30, 2021. This trademark is owned by Pfizer Inc.. The DAXSINIG trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, ophthalmological, psychiatric, respiratory, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, liver disorders, erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations, namely, antifungal preparations, dermatological preparations and smoking cessation preparations; vaccines for human use
daxsinig

General Information

Serial Number87669502
Word MarkDAXSINIG
Filing DateThursday, November 2, 2017
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, August 30, 2021
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 29, 2018

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, ophthalmological, psychiatric, respiratory, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, liver disorders, erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations, namely, antifungal preparations, dermatological preparations and smoking cessation preparations; vaccines for human use

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, November 13, 2017
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NamePfizer Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10017
Party NamePfizer Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10017

Trademark Events

Event DateEvent Description
Monday, August 30, 2021ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, August 30, 2021ABANDONMENT - NO USE STATEMENT FILED
Wednesday, December 23, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, December 22, 2020EXTENSION 5 GRANTED
Thursday, December 3, 2020EXTENSION 5 FILED
Monday, December 21, 2020CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, December 4, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, December 4, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, December 4, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, December 3, 2020TEAS EXTENSION RECEIVED
Friday, May 8, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, May 6, 2020EXTENSION 4 GRANTED
Wednesday, May 6, 2020EXTENSION 4 FILED
Wednesday, May 6, 2020TEAS EXTENSION RECEIVED
Monday, May 4, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Monday, May 4, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, May 4, 2020TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Monday, May 4, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, May 4, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Monday, May 4, 2020TEAS CHANGE OF OWNER ADDRESS RECEIVED
Saturday, December 14, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, December 12, 2019EXTENSION 3 GRANTED
Thursday, December 12, 2019EXTENSION 3 FILED
Thursday, December 12, 2019TEAS EXTENSION RECEIVED
Wednesday, June 26, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, June 24, 2019EXTENSION 2 GRANTED
Monday, June 24, 2019EXTENSION 2 FILED
Monday, June 24, 2019TEAS EXTENSION RECEIVED
Wednesday, December 12, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, December 10, 2018EXTENSION 1 GRANTED
Monday, December 10, 2018EXTENSION 1 FILED
Monday, December 10, 2018TEAS EXTENSION RECEIVED
Tuesday, July 24, 2018NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, May 29, 2018OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 29, 2018PUBLISHED FOR OPPOSITION
Wednesday, May 9, 2018NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, April 23, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, April 19, 2018TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, April 18, 2018CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, April 18, 2018TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, February 8, 2018NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, February 8, 2018NON-FINAL ACTION E-MAILED
Thursday, February 8, 2018NON-FINAL ACTION WRITTEN
Friday, February 2, 2018ASSIGNED TO EXAMINER
Monday, November 13, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Monday, November 6, 2017NEW APPLICATION ENTERED IN TRAM

Related Keywords

daxsinig preparations disorders pharmaceutical dysfunction treatment liver erectile blood viral urological